Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in adult participants diagnosed with any form of an advanced or
progressive MSS CRC for which 1st and 2nd line standard therapy (at least one of which
contained fluorouracil) is no longer effective or is intolerable. This is a phase 1b,
multi-center, open label study designed to assess safety and tolerability of grapiprant in
combination with pembrolizumab, to determine the recommended phase 2 dose (RP2D) with
pembrolizumab, and to evaluate and characterize the PK of grapiprant alone and in combination
with pembrolizumab. Disease response, pharmacodynamics, and response biomarkers will also be
assessed.